Pharmacological Management of Type 2 Diabetes Mellitus: An Update

被引：66

作者：

El-Kaissi, Samer ^{[1
]}

Sherbeeni, Suphia ^{[1
]}

机构：

[1] King Fahad Med City, Specialized Diabet & Endocrine Ctr, Riyadh, Saudi Arabia

来源：

CURRENT DIABETES REVIEWS | 2011年 / 7卷 / 06期

关键词：

Type 2 diabetes mellitus; Insulin; Thiazolidinediones; Sulphonylurea; Metformin; Glucagon-like peptide-1; Dipeptidyl peptidase-IV inhibitor; Bromocriptine; Alpha glucosidase inhibitor; Colesevelam;

D O I：

10.2174/157339911797579160

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

While lifestyle modifications and metformin are the cornerstone of the initial management of type 2 diabetes mellitus, there is an increasing array of second and third-line pharmacological agents for this condition. These include sulphonylureas, insulin, thiazolidinediones and alpha-glucosidase inhibitors, with the more recent addition of glucagonlike peptide-1 agonists, dipeptidyl peptidase-IV inhibitors and pramlintide. Moreover, insulin analogues that better simulate endogenous insulin secretion have been developed. This review aims to provide an update on the current pharmacological management of type 2 diabetes mellitus, and to highlight the benefits and limitations of each treatment.

引用

页码：392 / 405

页数：14

共 171 条

[31] Pharmacologic therapy for type 2 diabetes mellitus [J].

DeFronzo, RA .

ANNALS OF INTERNAL MEDICINE, 1999, 131 (04) :281-303

[32] The Efficacy and Safety of Saxagliptin When Added to Metformin Therapy in Patients With Inadequately Controlled Type 2 Diabetes With Metformin Alone [J].

DeFronzo, Ralph A. ;

Hissa, Miguel N. ;

Garber, Alan J. ;

Gross, Jorge Luiz ;

Duan, Raina Yuyan ;

Ravichandran, Shoba ;

Chen, Roland S. .

DIABETES CARE, 2009, 32 (09) :1649-1655

[33] From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus [J].

DeFronzo, Ralph A. .

DIABETES, 2009, 58 (04) :773-795

[34] Effect of linagliptin monotherapy on glycaemic control and markers of β-cell function in patients with inadequately controlled type 2 diabetes: a randomized controlled trial [J].

Del Prato, S. ;

Barnett, A. H. ;

Huisman, H. ;

Neubacher, D. ;

Woerle, H. -J. ;

Dugi, K. A. .

DIABETES OBESITY & METABOLISM, 2011, 13 (03) :258-267

[35] Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial [J].

Diamant, Michaela ;

Van Gaal, Luc ;

Stranks, Stephen ;

Northrup, Justin ;

Cao, Dachuang ;

Taylor, Kristin ;

Trautmann, Michael .

LANCET, 2010, 375 (9733) :2234-2243

[36] Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].

Dormandy, JA ;

Charbonnel, B ;

Eckland, DJA ;

Erdmann, E ;

Massi-Benedetti, M ;

Kmoules, IK ;

Skene, AM ;

Tan, MH ;

Lefébvre, PJ ;

Murray, GD ;

Standl, E ;

Wilcox, RG ;

Wlhelmsen, L ;

Betteridge, J ;

Birkeland, K ;

Golay, A ;

Heine, RJ ;

Korányi, L ;

Laakso, M ;

Mokán, M ;

Norkus, A ;

Pirags, V ;

Podar, T ;

Scheen, A ;

Scherbaum, W ;

Schernthaner, G ;

Schmitz, O ;

Skrha, J ;

Smith, U ;

Taton, J .

LANCET, 2005, 366 (9493) :1279-1289

[37] Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes An Overview of Data from PROactive [J].

Dormandy, John ;

Bhattacharya, Mondira ;

de Bruyn, Anne-Ruth van Troostenburg .

DRUG SAFETY, 2009, 32 (03) :187-202

[38] Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study [J].

Drucker, Daniel J. ;

Buse, John B. ;

Taylor, Kristin ;

Kendall, David M. ;

Trautmann, Michael ;

Zhuang, Dangliang ;

Porter, Lisa .

LANCET, 2008, 372 (9645) :1240-1250

[39] The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes [J].

Drucker, Daniel J. ;

Nauck, Michael A. .

LANCET, 2006, 368 (9548) :1696-1705

[40] The insulinotropic effect of acute exendin-4 administered to humans: Comparison of nondiabetic state to type 2 diabetes [J].

Egan, JM ;

Clocquet, AR ;

Elahi, D .

JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (03) :1282-1290

← 1 2 3 4 5 6 7 8 9 10 →